Clinical Trial Search

Primary: Number of Participants With Adverse Reaction (AE) and Severe Adverse Reaction (SAE) — 1; 0; 0; 0 Participants

Primary: Period 1: Percent Absolute Oral Bioavailability (%F) for Mobocertinib — 36.7 percentage bioavailability

Primary: Percentage of Participants With Adverse Events — 100; 100.0; 100.0; 91.7 percentage of participants

Primary: The Bioequivalent (BE) Comparison of AUC0-inf of Monomethyl Fumarate (MMF) Between Treatments — 2984; 3116 ng*hr/mL

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness — 9; 4; 4; 14 Participants

Primary: Percentage of Study Participants With Skin Reactions Less Than 10% — 0; 2 Participants

Primary: Potential of Abametapir Lotion to Cause Irritation After Repeated Topical Application to the Healthy Skin of Humans. — 1.10; 0.70; 1.10; 49.15 score on a scale

Primary: To Establish the Safety and Tolerability of Single-agent AZD1775 in Patients With Refractory Solid Tumors — 6; 4; 6; 3 Participants

Primary: Galidesivir Safety and Tolerability, as Measured by the Number of Participants Experiencing Adverse Events. — 2; 0; 1; 4 participants

Primary: Children's Yale-Brown Obsessive Compulsive Scale Modified for Autism Spectrum Disorder (CY-BOCS-ASD) - Total Score — 14.81; 14.60; 14.94; 15.71 Score on a Scale

Primary: Part 1: Peak Maximum Plasma Concentration (Cmax) of Apremilast — 451; 459 ng/mL

Primary: Cmax (Maximum Observed Plasma Concentration) — 124.6; 135.5; 158.6; 143.7 ng/mL

Primary: The Maximum Tolerated Dose (MTD) of BI 836909 — 400 Microgram Per Day (μg/d)

Primary: Maximum (Peak) Plasma Concentration (Cmax) of Brexpiprazole — 23.31; 24.24; 23.75 ng/mL

Primary: Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs (STEAEs) — 9; 6; 9; 4 Participants